Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Comorbidity – a publishing phenomenon

February 14, 2018

…comorbidity literature was clinical depression. “Depression” was the most common comorbidity across several disciplines, including Psychiatry, Neurology/Neurosciences, General and Internal Medicine, Geriatrics, Pharmacology, Endocrinology, and Public/Environmental/Occupational Health. The most prolific authors were Dr. Ronald C Kessler from Harvard Medical School, with 331 articles on comorbidity; his Harvard colleague Dr. Joseph Biederman (248 a…

ECTRIMS/EAN publish new MS treatment guidelines

January 30, 2018

…se severity/activity; drug safety profile; and accessibility of the drug. 5-7- Active secondary-progressive MS: Consider treatment with interferon-1a SC or IFN-1b SC (weak evidence); mitoxantrone (weak evidence); ocrelizumab or cladribine (weak). 8- Primary-progressive MS: Consider treatment with ocrelizumab. 9- Consult the Summary of Product Characteristics for dosage, special warnings and precautions for use, contraindications and monitoring of…

2017 U.S. drug approvals in neurology and psychiatry

January 19, 2018

…nvoluntary Movement Scale (AIMS) scores versus placebo (least-squares mean -3.0 vs. -1.6); treatment was associated with low rates of psychiatric adverse events, and no worsening of parkinsonism (Fernandez et al. Neurology 2017;88:2003-2010). Valbenzazine (Ingrezza, Neurocrine): this agent, a vesicular monoamine transporter-2 inhibitor, was the first to receive approval for tardive dyskinesia, but only maintained its solo status for four months be…

Long-term efficacy, safety of DMTs in MS

December 20, 2017

…h 6-month clinical disability improvement was 21%, and 74% were progression-free. With respect to MRI measures, 68% were free of new/enlarging T2 lesions, 91% had no Gd+ lesions and 85% had no new T1 hypointense lesions (Arnold et al. ECTRIMS 2017; abstract P1189). Brain atrophy, as assessed by brain parenchymal fraction (BPF), was normalized in Year 2 of treatment (-0.25%), and remained low in Years 6 (-0.17%) and 7 (-0.16%). In the group origina…